Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Terminated 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Vaginal Atrophy 1Urogenital Abnormalities 1Urinary Tract Infections 1Dysuria 1Dyspareunia 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Replens × Clear all
NCT04493333 2024-11-27

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

University of Arkansas

Phase 2 Terminated
8 enrolled 11 charts
Breast

Vaginal Atrophy

NCT03185169 2018-07-26

GSM

Alta Bates Summit Medical Center

Phase EARLY_PHASE1 Terminated
14 enrolled

Dyspareunia, Urinary Tract Infections, Urogenital Abnormalities, Dysuria

Data powered by HemOnc (CC BY 4.0) Colophon âš¡